MB Therapeutics emerges to offer tailored 3D printed medications

MB Therapeutics was founded to offer a new generation of 3D printed medications to patients. In the future, your drugs will be produced on-demand and customized to meet your specific needs.

The French startup is the result of over 8 years of experience, led by Dr. Stéphane Roulon at Sanofi and Dr. Ian Soulairol at the Faculty of Pharmacy of the University of Montpellier and the University Hospital Center of Nîmes. These research efforts led to a collaboration with Lynxter, a company based in Bayonne specializing in developing and producing industrial 3D printers.

Over the years, this collaboration fostered friendship and a shared desire to go further for the benefit of patients. It’s through this partnership that MB Therapeutics was founded in 2023 by Stéphane Roulon and Ian Soulairol. By 2026, patients will be able to benefit from personalized medications.

A new generation of 3D printed medications

MB Therapeutics was born because patients, especially children, deserve medications tailored to their needs and 3D printed medications are the only way to truly deliver on this front.

“We are excited to launch MB Therapeutics and provide innovative solutions to meet the needs of patients in personalized medicine, especially those of children,” said Dr. Stéphane Roulon, co-founder of the company.

Currently, for certain medical conditions, the pharmaceutical industry does not meet the needs of children. That’s why pharmacists prepare medications with customized dosages (38% of children receive at least one medication prepared by a pharmacist). However, “We do not have a process for automatically producing customized solid oral forms,” said Dr. Ian Soulairol, the company’s co-founder and hospital pharmacist. Capsules and tablets are not suitable for children in terms of size and quantity of active ingredients. Furthermore, liquid suspensions carry a risk of administration errors. In fact, 40% of parents make dosing errors when administering medication to their children.

With the MB Therapeutics solution, pharmacists will be able to produce on-demand, personalized dispersible medications that are easy to administer and have the correct dosage, preventing any errors.

Industrial sovereignty and waste reduction

Using 3D printing technology, MB Therapeutics enables pharmacists to produce oral forms tailored to the specific needs of each patient. The solution can address supply shortages by giving hospital pharmacies and community pharmacies with compounding capabilities the ability to produce medications with industrial quality automatically. Moreover, this solution contributes to healthcare improvement by reducing medication waste, which amounts to 15,000 tons of materials in France alone.

It is possible to produce medications with personalized dosages and also modify their forms to make them easier to swallow. Multiple active ingredients can be combined to reduce the number of medications to be taken, especially for elderly individuals, for example.

MB Therapeutics collaborates closely with healthcare professionals, including the University Hospital Center of Nîmes, to develop customized medication production solutions for children with illnesses. The company is confident that the use of 3D printing technology can have a significant impact on the quality of life for children and their families.